Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Cardiff Oncology Q2 2024 GAAP EPS $(0.26) Misses $(0.25) Estimate, Sales $163.000K Beat $58.750K Estimate

Author: Benzinga Newsdesk | August 08, 2024 05:52pm
Cardiff Oncology (NASDAQ:CRDF) reported quarterly losses of $(0.26) per share which missed the analyst consensus estimate of $(0.25) by 4 percent. This is a 4 percent decrease over losses of $(0.25) per share from the same period last year. The company reported quarterly sales of $163.000 thousand which beat the analyst consensus estimate of $58.750 thousand by 177.45 percent. This is a 50.93 percent increase over sales of $108.000 thousand the same period last year.

Posted In: CRDF


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist